<DOC>
	<DOCNO>NCT02143167</DOCNO>
	<brief_summary>Prolonged-release fampridine ( SR-fampridine ) improve walk capacity approximately 40 % MS patient suffer overcome partly total conduction block due demyelination . Resistance train show provide kind benefit patient target muscular component motor unit . Thus combine two likely see synergistic effect . This trial design double blind , randomize placebo control trial subsequent cross-over . Participants two arm go progressive training program target low limb . For 24 week one group receive SR-fampridine receives placebo . end another four week train cross-over performed .</brief_summary>
	<brief_title>Resistance Training Amino Pyridine Multiple Sclerosis</brief_title>
	<detailed_description>See</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>4-Aminopyridine</mesh_term>
	<criteria>Patients relapse remit multiple sclerosis ( RRMS ) , secondary progressive multiple sclerosis ( SPMS ) primary progressive multiple sclerosis ( PPMS ) fulfil McDonald criterion Expandend Disability Status Scale ( EDSS ) 36.5 Pyramidal Functional Score ≥ 2 Participants must able transport self gym University Southern Denmark Participants must able complete T25FW SSST Fertile female participant oblige use hormonal contraceptive measure History epileptic seizure MS relapse change disease modify treatment ( DMT ) within 60 day Cancer within five year Blood pressure ≥ 160/100 Severe arrhythmia ischaemic heart disease unexplained abnormal cardiac auscultation ≥ ALT 90 U/l , ≥ BSP 210 U/l , ≥ γGT 230 U/l GFR &lt; 80 ml/min . History severe pulmonary disease unexplained abnormal pulmonary auscultation Pregnancy Breastfeeding Allergy substance contain prolonged release Fampridine tablets Concomitant treatment carvedilol , propranolol metformin .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>